0000000000293862

AUTHOR

Chandrasekhar Bal

showing 3 related works from this author

Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot …

2021

Background: This exploratory study was to assess clinical and safety data with a novel fibroblast activation protein inhibitor-based targeted theranostics as a salvage treatment option in radioiodi...

AdultMaleEndocrinology Diabetes and MetabolismSalvage treatmentIndiaPilot ProjectsEndocrinologyFibroblast activation protein alphaRefractoryPositron Emission Tomography Computed TomographyMedicineHumansProspective StudiesThyroid NeoplasmsPrecision MedicineThyroid cancerProtein Kinase InhibitorsAgedbusiness.industryPhenylurea CompoundsMiddle AgedSorafenibmedicine.diseaseCancer researchQuinolinesFemalebusinessThyroid : official journal of the American Thyroid Association
researchProduct

Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases.

2017

Bone metastases, often a consequence of breast, prostate, and lung carcinomas, are characterized by an increased bone turnover, which can be visualized by positron emission tomography (PET), as well as single-photon emission computed tomography (SPECT). Bisphosphonate complexes of 99mTc are predominantly used as SPECT tracers. In contrast to SPECT, PET offers a higher spatial resolution and, owing to the 68Ge/68Ga generator, an analog to the established 99mTc generator exists. Complexation of Ga(III) requires the use of chelators. Therefore, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), NOTA (1,4,7-triazacyclododecane-1,4,7-triacetic acid), and their derivatives, are ofte…

diagnosismedicine.medical_treatmentPharmaceutical ScienceReview030218 nuclear medicine & medical imagingBone remodeling03 medical and health scienceschemistry.chemical_compound0302 clinical medicinebone metastasesDrug DiscoverymedicineDOTAbisphosphonatestherapymedicine.diagnostic_testbusiness.industryBisphosphonate177Lu68GachemistryPositron emission tomography030220 oncology & carcinogenesisMolecular MedicineNuclear medicinebusinessEmission computed tomographyPharmaceuticals (Basel, Switzerland)
researchProduct

68Ga- und 177Lu-markierte Bisphosphonate als Knochenmetastasen-Theranostika

2015

Der erhohte Metabolismus der Knochenmatrix kann zum einen mit der SPECT- und zum anderen mit der PET-Technik visualisiert werden. Als SPECT-Nuklid wird uberwiegend 99 mTc in Form von [99mTc]Bisphosphonat-Komplexen verwendet. Die PET bietet im Gegensatz zur SPECT eine hohere lokale und temporale Auflosung. Mit dem 68Ge/68Ga-Generatorsystem existiert ein mittlerweile bewahrtes PET-Pendant zum etablierten 99mTc-Generator. Neuartige Bisphosphonate (BP) in Kombination mit makrozyklischen Chelatoren sind derzeit weltweit Gegenstand der Forschung. Zur Komplexierung von Ga(III) werden haufig DOTA und NOTA sowie deren Derivate verwendet. Speziell im Fall von DOTA-Derivaten bieten DOTA-BP die Moglich…

GynecologyPhysicsmedicine.medical_specialtyOncologymedicineDer Nuklearmediziner
researchProduct